Article

High-Dose Melphalan Significantly Increases Mutational Burden in Multiple Myeloma Cells at Relapse: Results from a Randomized Study in Multiple Myeloma

2020-11-05

Abstract excerpt

We recently shown that high-dose melphalan (HDM) followed by autologous stem cell transplant (ASCT) as first line therapy in young (<66 yrs) multiple myeloma (MM) patients significantly improves progression-free survival (IFM/DFCI 2009 study). However, the impact of alkylating agent melphalan inducing N-alkylpurine-monoadducts forming interstrand crosslinks (ICLs) in surviving myeloma cells remains an important bi...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: d414e642-06bd-554a-ab62-f674b5c84720
DOI: 10.1182/blood-2020-139014

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

High-Dose Melphalan Significantly Increases Mutational Burden in Multiple Myeloma Cells at Relapse: Results from a Randomized Study in Multiple MyelomaDOI 10.1182/blood-2020-139014Read

The mutagenic impact of melphalan in multiple myeloma.Semantic proximity Read

Single-cell sequencing reveals the mechanisms of multiple myeloma progression: clarity or confusion?Semantic proximity Read

A Comprehensive Review of the Genomics of Multiple Myeloma: Evolutionary Trajectories, Gene Expression Profiling, and Emerging Therapeutics.Semantic proximity Read

Comprehensive characterization of the mutational landscape in multiple myeloma cell lines reveals potential drivers and pathways associated with tumor progression and drug resistanceSemantic proximity Read

Establishment and characterization of multiple myeloma cell lines from a single patient’s disease course immortalizes clonal heterogeneitySemantic proximity Read

Accelerated single cell seeding in relapsed multiple myeloma.Semantic proximity Read

Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergenceSemantic proximity Read

Utilizing next-generation sequencing in the management of multiple myeloma.Semantic proximity Read

Accelerated single cell seeding in relapsed multiple myelomaSemantic proximity Read

Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathwaysSemantic proximity Read

ctDNA improves prognostic prediction for patients with relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone.Semantic proximity Read

Multiple Myeloma Insights from Single-Cell Analysis: Clonal Evolution, the Microenvironment, Therapy Evasion, and Clinical ImplicationsSemantic proximity Read